Vitramyn™ tablets are formulated to provide daily vitamin supplementation for adult men and women, helping support overall nutritional wellness. With folate, Vitramyn™ may be especially beneficial for women during the pre-pregnancy, pregnancy, and post-pregnancy periods by supporting healthy folate levels and helping address anemia related to folate deficiency.
The recommended dosage is one (1) Vitramyn™ tablet daily, taken between meals or as directed by a physician. Vitramyn™ tablets are not recommended for use in children under 12 years of age.
Do not use if the seal under the bottle cap is broken. KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.
www.fda.gov/medwatchEach tablet contains:
Vitamin A (as retinyl acetate)……………….. 1500 mcg RAE (5000 IU)
Vitamin C (as ascorbic acid)……………….……………… 120 mg
Vitamin D3 (as cholecalciferol)…………….……. 20 mcg (800 IU)
Vitamin E (as dl-Alpha-Tocopheryl Acetate)……….....……. 30 mg
Thiamin (as thiamine mononitrate)…………...……………… 3 mg
Riboflavin.....................…………………………...…………. 3.4 mg
Niacin (as niacinamide)…………………………....………… 20 mg
Vitamin B6 (as pyridoxine hydrochloride)………….………. 20 mg
Folate (as L-5-Methyltetrahydrofolate calcium salt)……….. 1700 mcg DFE (1000 mcg L-5-Methylfolate)
Vitamin B12 (as cyanocobalamin)………………….……….. 8 mcg
Calcium (as calcium carbonate)……………………...……. 200 mg
Magnesium (as magnesium oxide)……………………...… 200 mg
Zinc (as zinc oxide)………………………………………....... 25 mg
Selenium (as selenium amino acid chelate)……………….55 mcg
Manganese (as manganese sulfate)………………………. 2.3 mg
Chromium (as chromium polynicotinate)………………..... 35 mcg
Molybdenum (as molybdenum amino acid chelate)……... 45 mcg
Other Ingredients:
Croscarmellose sodium, crospovidone, magnesium stearate, microcrystalline cellulose, organic cocoa powder, silicon dioxide, stearic acid, clear coating: hydroxypropyl methylcellulose, polyethylene glycol 400, organic guar gum, organic maltodextrin, organic sunflower lecithin, organic sunflower oil.
Vitramyn™ tablets are formulated to provide daily vitamin supplementation for adult men and women, helping support overall nutritional wellness. With folate, Vitramyn™ may be especially beneficial for women during the pre-pregnancy, pregnancy, and post-pregnancy periods by supporting healthy folate levels and helping address anemia related to folate deficiency.
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
Administration of folic acid alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B12 is deficient.
Folate in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive.
There is a potential danger in administering folate to patients with undiagnosed anemia, since folate may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before the correct diagnosis is made. Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia.
The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered.
Vitramyn™ is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with antiplatelet
agents (e.g., aspirin, clopidogrel) and anticoagulants (e.g., heparin).
Allergic sensitization has been reported following both oral and parenteral administration of folate derivatives.
Adverse reactions have been reported with individual vitamins and minerals, generally at levels substantially higher than those contained in this product.
However, allergic and idiosyncratic reactions may occur even at lower levels.
Gastrointestinal intolerance (e.g., nausea, abdominal discomfort) has been reported with certain vitamins and minerals, particularly at higher doses.
Call your doctor about side effects. To report side effects, call
PureTek Corporation at
1-877-921-7873 or
FDA at
1-800-FDA-1088 or
www.fda.gov/medwatch.
The recommended dosage is one (1)
Vitramyn™ tablet daily, taken between meals or as directed by a physician.
Vitramyn™ tablets are not recommended for use in children under 12 years of age.
Vitramyn™ is supplied as beige, speckled, oblong, film-coated, caplet-shaped tablets in bottles of 30 (NDC 59088-193-54). Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.
Store at controlled room temperature 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Avoid excessive heat.
Do not use if the seal under the bottle cap is broken.
KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.
Manufactured in the USA by:
PureTek Corporation
Panorama City, CA 91402
Questions? Call toll-free:
1-877-921-7873
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 59088-193-54 | EA - Each | 59088-193 | 920d8118-431a-490d-b121-0a8b06ba384b | 1 | 2021-09-07 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 59088-193 | 59088-193-54 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 4 | 2024-12-03 | full-release | 2026-05-31 21:18:46 |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vitramyn | FOLIC ACID | PureTek Corporation | c8af7616-5178-6df0-e053-2a95a90a334d | 2026-06-18 | Warnings, Adverse reactions | 59088-193-54 59088-193 59088019354 548ee394-41b9-d346-e063-6394a90a0773 c8af7616-5178-6df0-e053-2a95a90a334d |
Adverse event summaries are temporarily unavailable. Other product information remains available.